Status:
COMPLETED
Withdrawal Versus Continuation of Amiodarone in Successfully Treated Patients With Persistent Atrial Fibrillation
Lead Sponsor:
University Medical Center Groningen
Conditions:
Persistent Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Amiodarone is considered to be the most effective antiarrhythmic drug in the prevention of persistent atrial fibrillation. It can however cause many adverse events, both cardiac and non-cardiac. Long-...
Eligibility Criteria
Inclusion
- history of persistent atrial fibrillation, necessitating at least one electrical cardioversion
- presence of sinus rhythm during the last 6 months, while on amiodarone treatment without adverse events related to amiodarone
- clinically stable
- age \> 18 years
- written informed consent
Exclusion
- sinus rhythm maintenance is preferable (because of atrial fibrillation related morbidity or any other reason)
- symptomatic heart failure NYHA III or IV
- unstable angina pectoris
- hemodynamically significant valvular disease
- concomitant treatment with other class I or III antiarrhythmic drug
- PCI,CABG, other cardiac surgery or major non-cardiac surgery within the last three months
- recent myocardial infarction (\< 3 months)
- presence of any disease that is likely to shorten life expectancy to \< 1 year
Key Trial Info
Start Date :
August 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00845780
Start Date
August 1 2000
End Date
June 1 2009
Last Update
June 24 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Groningen
Groningen, Provincie Groningen, Netherlands, 9700 RB